Covid-19: Gennova’s mRNA vaccine gets DCGI approval

Did not receive any bids that reflected Boots’ potential value, said the retail major
Says will invest if the product turns out to be gamechanger in terms of technology, costs
Plans to buy from open market at a maximum price of ₹4,600 per share